AGEN1423

Phase 2Small molecule

WWeill Medical College of Cornell University

AGEN1423 is one of 54 small molecule programs targeting Advanced Pancreatic Ductal Adenocarcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Advanced Pancreatic Ductal AdenocarcinomaActive, not recruiting

Colorectal CancerRecruiting

Advanced Pancreatic Ductal AdenocarcinomaPhase 2

Active, not recruiting

Colorectal CancerPhase 2

Recruiting

Competition

Competitive Landscape

268 competitors in Colorectal Cancer

#DrugCompanyPhaseTrials

Opdivo

Bristol-Myers Squibb

Phase 3

24 2

Fudr

Pfizer

Phase 3

16 3

Adrucil

EElorac, Inc.

Phase 3

87 4

Tecentriq

Roche

Phase 3

6 5

Decadron

AAspen Global Incorporated

Phase 3

7 6

Balstilimab

AAgenus Inc.

Phase 3

10 7

Zanzalintinib

Merck & Co.

Phase 3

1 8

Serplulimab

Shanghai Henlius Biotech

Phase 3

2 9

BL-M07D1

SSichuan Baili Pharmaceutical Co., Ltd.

Phase 3

1 10

Calcium Levofolinate

FFujian Cancer Hospital

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Recruiting

Colorectal Cancer

NCT06300463

Q2 2027

Phase 2Active, not recruiting

Advanced Pancreatic Ductal Adenocarcinoma

NCT05632328

Clinical

Trials by Indication[1]

Colorectal Cancer1 trial

Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases

Recruiting·WWeill Medical College of Cornell University·Phase 2·NCT06300463·24 enrolled

Advanced Pancreatic Ductal Adenocarcinoma1 trial

A Phase 2 Study of AGEN1423, an Anti-CD73-TGFβ-Trap Bifunctional Antibody, in Combination With Botensilimab, With or Without Chemotherapy in Subjects With Advanced Pancreatic Cancer.

Active, not recruiting·BBruno Bockorny·Phase 2·NCT05632328·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for AGEN1423. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AGEN1423 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AGEN1423. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Weill Medical College of Cornell University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: WWeill Medical College of Cornell University

AGEN1423

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q2 2027

Trials by Indication[1]

Colorectal Cancer1 trial

Advanced Pancreatic Ductal Adenocarcinoma1 trial

References

Drug Info

Quick Facts

Related News